Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A randomized controlled trial involving a telemedicine-based approach for the management of patients with acute coronary syndrome had several clinical benefits relative to standard of care.
In a randomized clinical trial, alerts based on the detection of abnormalities in electrocardiograms using a deep learning algorithm reduced all-cause mortality at 90 days in patients admitted to hospital emergency or internal medicine departments.
AI-enabled wellness apps exist in a regulatory gray area and may pose risks if used to manage mental health issues; this Perspective outlines the possible risks to users and the implications for app developers and regulators.
A survey of 23,000 adults in 23 countries in 2023 reports that the pandemic experience reduced participants’ willingness to be vaccinated for COVID-19 and receive routine vaccinations and reduced trust in recommendations from public health authorities.
An argument framework, grounded in the sciences of reasoning, provides an alternative to medicine’s measurement framework for evaluating and synthesizing evidence in healthcare.
In a case series of six patients with multidrug-resistant rheumatoid arthritis, the CD19xCD3-targeting bispecific T cell engager blinatumomab reduced disease activity and led to reductions in autoantibodies.
Tailored to detect and prevent potential medication direction errors in a digital pharmacy data processing pipeline, a large language model is shown to increase efficiency and decrease burden for technicians and pharmacists in a prospective application.
QR4 is a new cardiovascular disease (CVD) risk score developed and evaluated in 16.9 million people that has better performance than other commonly used CVD risk scores. It includes nine new risk factors associated with increased risk of developing CVD (for example, a heart attack or stroke) over the next 10 years.
In a phase 2 trial, nivolumab achieved a response rate of 58% in patients with mismatch-repair-deficient gynecological cancers, meeting the primary endpoint, and genomic and immunologic features correlated with response.
Food allergy treatment is undergoing a paradigm shift with new therapies emerging, including the recent FDA approval of omalizumab — but without evidence of disease modification and with uncertain quality-of-life improvement, it may not be a panacea for all.
An mRNA-based drug aims to replace a faulty enzyme and restore metabolic function in children with propionic acidemia — with encouraging early clinical results.
In a multicenter clinical trial, patients with early-stage Parkinson’s disease treated with lixisenatide, a drug currently used for the treatment of diabetes, showed improvement in their motor scores compared with those on placebo.
AI models for tasks such as pathology and dermatology struggle to generalize to new patient groups or hospitals that they were not trained on; learning more robust features from unlabeled data could prevent overfitting to the training distribution and thereby increase fairness.
The cellular and molecular mechanisms underlying the health impacts of climate change must be better understood in order to plan interventions that mitigate harm.